
    Original Text: Known intolerance to trastuzumab that persists after appropriate medical management. Patients who have a history of prior intolerance to trastuzumab that is controlled after medical management and who tolerate trastuzumab thereafter without reactions are eligible to participate
    Disease/Condition: none
    Procedure: Trastuzumab
    Biomarker: none
    Computable Rule: "Known intolerance to trastuzumab that persists after appropriate medical management" is False OR "Patients who have a history of prior intolerance to trastuzumab that is controlled after medical management and who tolerate trastuzumab thereafter without reactions" is True

Criterion:
    Patients with metastatic breast cancer who have received no more than one chemotherapy regimen for metastatic disease, including adjuvant therapy, and whose tumors express HER2 protein by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH).

Output:
    Original Text